Floatz logo

BISOPROLOL

Cardiotoxicity

Azienda Ospedaliero-Universitaria CareggiSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Cardiotoxicity cohort.

Asset / SponsorPhaseRating
POTASSIUM
Tufts Medical Center
Phase 3BB
Orlistat
University of British Columbia
Phase 4BB
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3BB
WARFARIN
Massachusetts General Hospital
Phase 3BB
VITAMIN D
Phase 3BB

View all 36 →

Same molecule, other indications

BISOPROLOL is also rated in:

hypertensive disorderDormant
BB
Indicative ·
65 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →